- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Tulipano Stephen J	2. Issuer Name and Ticker or Trading Symbol JAVELIN PHARMACEUTICALS, INC [ JAV ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                      _____ 10% Owner __ X __ Officer (give title below)      _____ Other (specify below) CFO and Secretary
(Last)          (First)          (Middle) C/O JAVELIN PHARMACEUTICALS, INC, 125 CAMBRIDGEPARK DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 6/30/2010
(Street) CAMBRIDGE, MA 02140 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	6/30/2010		U		10115   (1)	D	$2.20	0	D
Restricted Stock Units	7/2/2010		D		12500   (2)	D	$2.20	0	D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.70	7/2/2010		D			150000   (3)	(4)	5/1/2016	Common Stock	150000	$0	0	D
Stock Option (right to buy)	$4.98	7/2/2010		D			45000   (3)	(5)	1/3/2017	Common Stock	45000	$0	0	D
Stock Option (right to buy)	$3.53	7/2/2010		D			60000   (3)	(6)	1/9/2018	Common Stock	60000	$0	0	D
Stock Option (right to buy)	$1.07	7/2/2010		D			89400   (7)	(8)	1/23/2019	Common Stock	89400	$0	0	D
Stock Option (right to buy)	$1.15	7/2/2010		D			44700   (9)	(10)	3/16/2019	Common Stock	44700	$0	0	D
Stock Option (right to buy)	$1.26	7/2/2010		D			75000   (11)	(12)	5/1/2019	Common Stock	75000	$0	0	D

Explanation of Responses:
( 1)	Pursuant to the Agreement and Plan of Merger, dated April 17, 2010, by and among Hospira, Inc., Discus Acquisition Corporation ("Purchaser") and Javelin Pharmaceuticals, Inc. (the "Company"), Purchaser merged with and into the Company on July 2, 2010 (the "Merger"). These shares, which were outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were immediately canceled and converted at the effective time of the Merger into the right to receive cash consideration equal to $2.20 per share.
( 2)	These Restricted Stock Units, which were outstanding and unexercised immediately prior to the Effective Time, accelerated and were immediately canceled, terminated and converted into the right to receive a cash payment equal to $2.20 per share.
( 3)	These options, which were outstanding and unexercised immediately prior to the Effective Time were immediately canceled and terminated.
( 4)	These options vest in 3 equal annual installments beginning after 5/1/2007.
( 5)	These options vest in 3 equal annual installments beginning after 1/3/2008.
( 6)	These options vest in 3 equal annual installments beginning after 1/9/2009.
( 7)	These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $101,022.00, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 8)	These options vest in 3 equal annual installments beginning after 1/23/2010.
( 9)	These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $46,935.00, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 10)	These options vest in 3 equal annual installments beginning after 3/16/2010.
( 11)	These options, which were outstanding and unexercised immediately prior to the Effective Time, accelerated and were immediately canceled, terminated and converted into the right to receive a cash payment of $70,500.00, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 12)	These options vest in 2 equal installments on the first and second anniversary of the grant date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Tulipano Stephen J C/O JAVELIN PHARMACEUTICALS, INC 125 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140			CFO and Secretary

Signatures
/s/ Stephen J. Tulipano		7/2/2010
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.